|
ST segment elevation myocardial infarction
|
0.030 |
Biomarker
|
disease |
BEFREE |
Materials and Methods This secondary analysis of two prospective multicenter cardiac MRI studies (AIDA STEMI [NCT00712101] and TATORT NSTEMI [NCT01612312]) included 1235 study participants with ST-elevation myocardial infarction (<i>n</i> = 795) or non-ST-elevation myocardial infarction (<i>n</i> = 440) between July 2008 and June 2013.
|
31526253 |
2019 |
|
Non-ST Elevated Myocardial Infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
Materials and Methods This secondary analysis of two prospective multicenter cardiac MRI studies (AIDA STEMI [NCT00712101] and TATORT NSTEMI [NCT01612312]) included 1235 study participants with ST-elevation myocardial infarction (<i>n</i> = 795) or non-ST-elevation myocardial infarction (<i>n</i> = 440) between July 2008 and June 2013.
|
31526253 |
2019 |
|
Coronary Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Integrative analysis of vascular endothelial cell genomic features identifies AIDA as a coronary artery disease candidate gene.
|
31287004 |
2019 |
|
Coronary heart disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Integrative analysis of vascular endothelial cell genomic features identifies AIDA as a coronary artery disease candidate gene.
|
31287004 |
2019 |
|
Coronary Artery Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We validate one CAD locus, by engineering a deletion of the TNFα-sensitive regulatory element using CRISPR/Cas9 and measure the effect on the expression of the novel CAD candidate gene AIDA.
|
31287004 |
2019 |
|
Pneumonia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, <i>aidA</i> expression in the first type of strain was not regulated in the presence of environmental stress factors such as the 3-oxo-C12-HSL molecule (substrate of AidA protein, QQ activation) or H<sub>2</sub>O<sub>2</sub> (inhibitor of AidA protein, QS activation).However, in the <i>A. baumannii</i> strains isolated from patients with non-bacteraemic pneumonia, <i>aidA</i> gene expression was regulated by stressors such as 3-oxo-C12-HSL and H<sub>2</sub>O<sub>2</sub>.
|
30619184 |
2018 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
AIDA Selectively Mediates Downregulation of Fat Synthesis Enzymes by ERAD to Retard Intestinal Fat Absorption and Prevent Obesity.
|
29617643 |
2018 |
|
ST segment elevation myocardial infarction
|
0.030 |
Biomarker
|
disease |
BEFREE |
CMR-FT is a superior measure of LV function and performance early after reperfused MI with incremental prognostic value for mortality over and above LV ejection fraction and infarct size.(Abciximab i.v.Versus i.c. in ST-segment elevation Myocardial Infarction [AIDA STEMI]; NCT00712101; Thrombus Aspiration in ThrOmbus Containing culpRIT Lesions in Non-ST-Elevation Myocardial Infarction [TATORT-NSTEMI]; NCT01612312).
|
29454776 |
2018 |
|
Non-ST Elevated Myocardial Infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
CMR-FT is a superior measure of LV function and performance early after reperfused MI with incremental prognostic value for mortality over and above LV ejection fraction and infarct size.(Abciximab i.v.Versus i.c. in ST-segment elevation Myocardial Infarction [AIDA STEMI]; NCT00712101; Thrombus Aspiration in ThrOmbus Containing culpRIT Lesions in Non-ST-Elevation Myocardial Infarction [TATORT-NSTEMI]; NCT01612312).
|
29454776 |
2018 |
|
Myocardial Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
CMR-FT is a superior measure of LV function and performance early after reperfused MI with incremental prognostic value for mortality over and above LV ejection fraction and infarct size.(Abciximab i.v.Versus i.c. in ST-segment elevation Myocardial Infarction [AIDA STEMI]; NCT00712101; Thrombus Aspiration in ThrOmbus Containing culpRIT Lesions in Non-ST-Elevation Myocardial Infarction [TATORT-NSTEMI]; NCT01612312).
|
29454776 |
2018 |
|
ST segment elevation myocardial infarction
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
STEMI patients ( n=738) included in the AIDA STEMI trial underwent primary percutaneous coronary intervention within 12 hours after symptom onset.
|
26691729 |
2017 |
|
Coronary Arteriosclerosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Impact of multivessel coronary artery disease on reperfusion success in patients with ST-elevation myocardial infarction: A substudy of the AIDA STEMI trial.
|
26691729 |
2017 |
|
Coronary heart disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Impact of multivessel coronary artery disease on reperfusion success in patients with ST-elevation myocardial infarction: A substudy of the AIDA STEMI trial.
|
26691729 |
2017 |
|
Coronary Artery Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Impact of multivessel coronary artery disease on reperfusion success in patients with ST-elevation myocardial infarction: A substudy of the AIDA STEMI trial.
|
26691729 |
2017 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Odontogenic Cysts
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical validation of chosen putative biomarkers revealed axin interaction partner and dorsalization-antagonist (AIDA), known as a protein that blocks activation of JNK signalling pathway, as a differential biomarker for KCOT lesions on an independent cohort of KCOT tissue samples in comparison with most prevalent intra-oseal lesions inflammatory odontogenic cysts.
|
25040847 |
2015 |
|
Odontogenic Tumors
|
0.010 |
Biomarker
|
group |
BEFREE |
Immunohistochemical validation of chosen putative biomarkers revealed axin interaction partner and dorsalization-antagonist (AIDA), known as a protein that blocks activation of JNK signalling pathway, as a differential biomarker for KCOT lesions on an independent cohort of KCOT tissue samples in comparison with most prevalent intra-oseal lesions inflammatory odontogenic cysts.
|
25040847 |
2015 |
|
Acute Promyelocytic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.
|
21385856 |
2011 |
|
Childhood Acute Promyelocytic Leukemia with PML-RARA
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results highlight the efficacy and feasibility of the AIDA protocol in the pediatric APL population.
|
15677559 |
2005 |
|
Acute Promyelocytic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that APL patients who are molecularly resistant to the AIDA protocol have no distinguishing features at presentation.
|
14754603 |
2004 |
|
Acute Promyelocytic Leukemia
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We investigated the prevalence and clinico-biological correlations of FLT3 ITDs and D835 mutations in 90 patients with acute promyelocytic leukemia (APL) receiving the AIDA protocol.
|
12399960 |
2002 |